Lukyanchuk O. V., Moskalenko A. M., Bokal I. I., Gozhenko A. I. ON THE STATE OF ENDOTHELIAL DESQUAMATION IN CANCER PATIENTS. Актуальні проблеми транспортної медицини / Actual problems of transport medicine / 2018;4(54):88-93. ISSN 1818-9385
DOI http://dx.doi.org/10.5281/zenodo.2525619
http://aptm.org.ua
ON THE STATE OF ENDOTHELIAL DESQUAMATION IN CANCER PATIENTS
O. V. Lukyanchuk1, A. M. Moskalenko1, I. I. Bokal1, A. I. Gozhenko2
1Odessa Regional Oncology Center
2SE “Research Institute for Medicine of Transport of the Ministry of Health Care of Ukraine”, Odessa
Abstract
Introduction. Hypercoagulation is one of the most important general changes in the body of cancer patients, the presence of which is taken into account both in the surgical and conservative treatment of cancer patients and requires adequate correction due to the possibility of thrombotic complications. The objective. To study the number of circulating endotheliocytes (CE) and assess the extent of endothelial damage in cancer patients before and after treatment with dacarbazine. Materials and research methods. The content of CE in 20 cancer patients before and after treatment with dacarbazine was studied. Dacarbazine was administered intravenously once at a dosage of 60-75 mg / m2 of a body surface. At 1-3 days after its introduction, a complete blood count, urinalysis, coagulogram were examined in the patients under observation. Results. A high content of CE at all the patients under observation was established. Chemotherapy is accompanied by an increase in CE content for more than twice. Conclusion. The tumor process increases desquamation of endothelium, which increases even more after chemotherapy.
Key words: endothelial desquamation, hypercoagulation, circulating endotheliocytes, cancer patients, dacarbazine
